Revolutionary AI Platform to Reshape Healthcare in Treating Intracranial Aneurysms
A groundbreaking AI platform developed by Quantitative Angiographic Systems Artificial Intelligence (QAS.AI) is set to redefine the treatment of intracranial aneurysms (IAs) and significantly improve patient outcomes. Led by biomedical engineer Ciprian Chip Ionita, QAS.AI aims to revolutionize the approach to IA treatment by utilizing cutting-edge AI technology to detect complications in real-time during surgery.
Intracranial aneurysms pose a significant global health risk, with nearly 500,000 deaths attributed to them annually. With this in mind, Ionita and his team at QAS.AI are developing innovative AI software designed to enhance the detection of complications and evaluate the likelihood of treatment success during surgery. Unlike existing AI solutions that focus on offline diagnosis and clinical workflow optimization, QAS.AI’s technology pushes boundaries by providing real-time prognosis tools for use in the operating room.
QAS.AI’s commendable efforts have recently been recognized with a $1 million Phase II grant from the National Science Foundation’s Small Business Technology Transfer program. This grant allows QAS.AI to further advance their research, refine their AI-based software, and prepare for clinical evaluations. These evaluations will take place at prominent institutes in Buffalo and Florida, enabling QAS.AI to gather crucial data and refine their platform for clinical use.
The key aspect of QAS.AI’s AI software lies in its ability to assess the likelihood of aneurysm healing during interventions. If the software predicts a low probability of healing within a year, this information is instantly shared with neurosurgeons, allowing them to adapt their treatment approach accordingly. The real-time assessment feature proves instrumental in closely monitoring patients and promptly responding to any changes in the aneurysm’s behavior.
To prepare for clinical evaluations, QAS.AI will utilize the Phase II grant to develop clinical-grade software that adheres to Health Insurance Portability and Accountability Act (HIPAA) regulations, ensures patient protection, and seamlessly integrates with surgical equipment. The chosen sites for these evaluations include the Gates Vascular Institute (GVI), Mercy Hospital of Buffalo, and the University of South Florida’s Department of Neurosurgery and Brain Repair. QAS.AI’s ultimate goal is to secure FDA approval for their AI software through further clinical trials that may require additional grants or private investments.
Beyond its potential clinical applications, QAS.AI’s AI platform also promises significant commercial impact. Medical imaging companies may experience a projected revenue boost of $1.1 billion in the U.S. markets alone, thanks to a projected 5% increase in scanner sales. Additionally, this innovative technology has the potential to reduce re-treatment costs by approximately $65,000 per case, resulting in an annual savings of $1.95 billion in the United States. The transformative potential of QAS.AI’s AI platform extends beyond financial gains, as it simultaneously enhances patient outcomes and improves operational efficiency within the medical imaging and healthcare industries.
Ciprian Ionita is optimistic about the progress of QAS.AI’s AI platform and expects the first clinical evaluation to be operational at the Gates Vascular Institute by August 2024, followed by evaluations at the other chosen locations. As QAS.AI continues to forge ahead with groundbreaking advancements, the integration of advanced AI technology into the surgical process offers hope for reducing mortality rates, curbing healthcare costs, and minimizing patient disabilities associated with intracranial aneurysms. The potential transformative impact of QAS.AI’s AI platform on both the medical imaging and healthcare industries aligns with the broader objective of improving patient care and operational efficiency.
